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Abstract
Asthma is a common chronic respiratory disease characterized by airway hyperresponsiveness (AHR). The genetics of
asthma have been widely studied in mouse and human, and homologous genomic regions have been associated with
mouse AHR and human asthma-related phenotypes. Our goal was to identify asthma-related genes by integrating AHR
associations in mouse with human genome-wide association study (GWAS) data. We used Efficient Mixed Model Association
(EMMA) analysis to conduct a GWAS of baseline AHR measures from males and females of 31 mouse strains. Genes near or
containing SNPs with EMMA p-values ,0.001 were selected for further study in human GWAS. The results of the previously
reported EVE consortium asthma GWAS meta-analysis consisting of 12,958 diverse North American subjects from 9 study
centers were used to select a subset of homologous genes with evidence of association with asthma in humans. Following
validation attempts in three human asthma GWAS (i.e., Sepracor/LOCCS/LODO/Illumina, GABRIEL, DAG) and two human
AHR GWAS (i.e., SHARP, DAG), the Kv channel interacting protein 4 (KCNIP4) gene was identified as nominally associated
with both asthma and AHR at a gene- and SNP-level. In EVE, the smallest KCNIP4 association was at rs6833065 (P-value 2.9e-
04), while the strongest associations for Sepracor/LOCCS/LODO/Illumina, GABRIEL, DAG were 1.5e-03, 1.0e-03, 3.1e-03 at
rs7664617, rs4697177, rs4696975, respectively. At a SNP level, the strongest association across all asthma GWAS was at
rs4697177 (P-value 1.1e-04). The smallest P-values for association with AHR were 2.3e-03 at rs11947661 in SHARP and 2.1e-
03 at rs402802 in DAG. Functional studies are required to validate the potential involvement of KCNIP4 in modulating
asthma susceptibility and/or AHR. Our results suggest that a useful approach to identify genes associated with human
asthma is to leverage mouse AHR association data.
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Introduction
Asthma is a common chronic respiratory disease with a rise in
prevalence over the past decades, affecting over 25 million
Americans and 300 million people world-wide [1,2]. Asthma is
characterized by airway hyperresponsiveness (AHR), a trait
distinguished by increased airway smooth muscle contractility in
response to certain exposures. The mouse is commonly used to
model the genetics of human diseases because mice are
physiologically similar to humans, the mouse genome has been
sequenced, and many tools exist that allow for direct testing of
genetic alterations in mice [3,4]. Although attempts to recreate all
of the features of human asthma in mice have not been successful
[5], many of the allergic asthmatic responses in mouse are similar
to the responses observed in humans [6,7]. The most common
asthma phenotype studied in the mouse is AHR, and several
regions that have been associated with mouse AHR are
homologous with genomic regions linked with asthma-related
phenotypes in human cohorts. For example, two linkage studies
[8,9] in mouse identified AHR quantitative trait loci (QTL) on
chromosome 7 that are homologous with human AHR QTL on
chromosome 19q observed in Hutterites and Chinese individuals
[10,11]. Mouse AHR QTL observed on chromosome 17 in three
studies [9,12,13] overlap with human chromosome 6p QTLs
identified in four studies of asthma and allergic phenotypes
[14,15,16,17]. Thus, it is likely that mouse and human share
genetic variants that predispose both species to asthma-related
phenotypes, and mouse AHR is an appropriate phenotype to
identify some of these shared genetic variants.
Genome-wide association analysis of mouse inbred strains can
provide a cost effective complement to traditional QTL methods
[18,19]. Such methods leverage the fact that laboratory mouse
strains, whose lineage is well known, are nearly isogenic due to
their inbred origin [20] and therefore, share large haplotype blocks
that are identical by descent. Assuming that phenotypic differences
observed between mouse strains are due to different variants
inherited within ancestral haplotypes, regions associated with a
trait can be narrowed by comparison of haplotypes across many
strains. The ability to narrow such regions efficiently is made
possible by genetic resources and bioinformatics tools, including
dense SNP sets for mouse strains [21,22] and association
algorithms [18,19]. Studies using mouse strain surveys have been
successful in identifying genes relevant to human disease, such as
HDL levels in blood [18]. A previous in silico QTL study of
baseline AHR in 36 female mouse strains identified eight possible
regions that could underlie differences in AHR among strains [23].
The results of this study have not been extensively validated or
evaluated in humans.
The genetic basis of asthma has been widely studied in humans
[24]. Most recently, multi-center, multi-cohort genome-wide
association studies (GWAS) of asthma have been carried out in
Europeans and diverse North American populations [25,26].
These and other GWAS have begun to identify loci (e.g. IKZF3-
ZPBP2-GSDMB-ORMDL3 locus, HLA-DQ, IL1RL1, IL18RL1,
IL33, TSLP, SLC22A5, SMAD3, and RORA) that are consistently
associated with asthma at statistical thresholds that leave little
doubt the results are truly significant. However, it is likely that
some of the findings that do not meet genome-wide significance
levels in these GWAS represent true associations that are
biologically relevant for asthma. The question of how to
distinguish true associations among the false positive ones is
challenging. In this work, we address this challenge by using
mouse baseline AHR association measures and searching among
previously published nominally significant EVE Consortium
GWAS meta-analysis results [26] to identify genes that may be
associated with asthma. After attempting to confirm our results in
three additional asthma GWAS and two AHR GWAS, we found
that the Kv channel interacting protein 4 (KCNIP4) is likely to be
related to asthma and AHR.
Results
Figure 1 is an overview of our study design. Measures of
baseline AHR in 31 mouse strains found that there was up to a
4.2-fold change in AHR slope across strains, with the smallest
slope (i.e. 0.40 SEM 0.10) corresponding to the C57BL/6J strain
and the largest slope (i.e. 1.67 SEM 0.20) corresponding to the
KK/H1J strain [Figure 2]. The complete AHR phenotype results
are freely available as project ‘‘Berndt1’’ in the Mouse Phenome
Database of the Jackson Laboratory. The EMMA results for AHR
slope did not contain any P-values that were significant after
correction for multiple comparisons (i.e. ,0.05/281,300=1.8e-
07) [Figure 3]. Nonetheless, some genomic regions had P-values
that were nominally significant and may indicate true associations
with AHR slopes. The set of 227 mouse genes within 50 kb of
SNPs with EMMA P-values ,0.001 was selected for further study.
Of the 227 top mouse genes, 145 had human orthologs,
according to the human-mouse HomoloGene map utilized.
Results from the EVE GWAS based on all samples and specific
to race/ethnic groups were obtained for all SNPs within 50 kb of
KCNIP4 as an Asthma Gene
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with a P-value ,0.001 in the EVE European American, African
and Caribbean American, Latino American and/or all subjects’
GWAS. The results in the vicinity of these 35 genes were explored
more carefully to ensure that 1) the AHR slope phenotype
distribution approximately matched the genotype distribution
across mouse strains, 2) the mouse association results were based
on SNPs with minor allele frequency .2/31, and 3) the
association results were supported by a region of LD in both
mouse and human. Two regions that included a total of five genes
met these criteria: 1) KCNIP4, a 1220.19 kb-long gene that was
covered (including 50 kb on either end) by 1,766 EVE combined
meta-analysis SNPs, and 2) PDZD2/GOLPH3/MTMR12/ZFR,a
732 kb-long region that was covered (including 50 kb on either
end) by 697 EVE European American analysis SNPs [Figure 4].
The smallest mouse EMMA p-values for these two regions were
9.1e-04 for Kcnip4 and 8.4e-04 for Pdzd2/Golph3/Mtmr12/Zfr. The
genotype distribution for mouse SNPs with these P-values in the
corresponding regions are shown in Figure 5. The EVE P-values
supporting the KCNIP4 association were from the combined meta-
analysis, and the lowest P-value (2.9e-04) was for SNP rs6833065.
The EVE P-values supporting the PDZD2/GOLPH3/MTMR12/
ZFR region of association were from the European American
results, and the lowest P-value (5.5e-04) was for SNP rs17526969.
We next attempted to replicate the asthma association findings
in two human cohorts: Sepracor/LOCCS/LODO/Illumina and
GABRIEL. We found that there was gene level replication for
KCNIP4, and, considering the genomic interval spanning four
genes, some regional replication for the PDZD2/GOLPH3/
MTMR12/ZFR association [Figure 6]. Each asthma GWAS had
a different top hit in each region, and only KCNIP4 showed
evidence of SNP-level replication at a nominally significant
threshold [Table 1]. Based on the replication results in GABRIEL
and Sepracor/LOCCS/LODO/Illumina, we attempted to repli-
cate the KCNIP4 findings in DAG. The lowest EVE P-value of
2.9e-04 at rs6833065 did not replicate in Sepracor/LOCCS/
LODO/Illumina or DAG, and data for this SNP was not available
in GABRIEL. The lowest GABRIEL association at rs469177 (P-
value 1.0e-03) was nominally significant in EVE and DAG, but not
Sepracor/LOCCS/LODO/Illumina. The lowest Sepracor/
LOCCS/LODO/Illumina association at rs7664617 (P-value
1.5e-03) was nominally significant in EVE, but data for this SNP
was not available in GABRIEL or DAG. The lowest combined P-
value across the four asthma GWAS was 1.1e-04 for rs4697177,
while the three SNPs with nominally significant P-values in 3/4
GWAS were rs4697177, rs6448072, and rs6856781. The allelic
frequencies and odds ratios for the top KCNIP4 SNPs are shown in
Table 2 and Table 3, respectively.
Because the mouse phenotype measured, baseline AHR, is not a
precise surrogate of human asthma, we also attempted to measure
the association of top EMMA SNPs with another related
phenotype for which GWAS data are available: human AHR
among asthmatics. Of the top two regions, KCNIP4 and PDZD2/
GOLPH3/MTMR12/ZFR, only KCNIP4 had gene-level replication
Figure 1. Study overview. Mouse association study (in pink): (A) Baseline AHR slope measures were obtained for 31 mouse strains, and these were
(B) used to perform an association study using EMMA software. (C) Mouse genes near or containing SNPs with p-values ,0.001 were selected for
follow-up study in human GWAS datasets. Integration of mouse results with human data (in blue): (D) HomoloGene maps were used to obtain human
homologous genes corresponding to the top mouse genes. (E) Genes with SNPs having p-values ,0.001 in the combined EVE meta-analysis or within
race/ethnic specific GWAS were selected for (F) replication in other human GWAS.
doi:10.1371/journal.pone.0056179.g001
KCNIP4 as an Asthma Gene
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same regions as the asthma GWAS studies [Figure 7]. At a SNP
level, there was no overlap between the strongest associations with
asthma vs. AHR in either the SHARP or DAG AHR GWAS
[Table 1].
Discussion
Many risk-modifying loci have been identified via human
GWAS studies for a wide range of complex diseases, including
asthma [27]. Over time, the number of loci identified has grown,
due in part to the greater statistical power of studies conducted.
The primary way in which increased statistical power has been
achieved is to conduct large-scale meta-analyses based on cohorts
from many smaller studies. While the number of associations that
pass genome-wide significance thresholds has increased, it is likely
that some true associations that represent biologically important
processes underlying diseases are present among the nominally
significant ones. Approaches to identify true associations that are
not among results meeting genome-wide significance levels in
GWAS include attempts to replicate nominally significant findings
in independent populations [26,28], to conduct functional studies
of top-ranked associations [29,30], and to use gene-based [31] and
pathway-based [32] methods. In this work, we have attempted to
use a mouse genome-wide association analysis based on a strain
survey of baseline AHR to identify asthma associations in humans.
The top two regions identified based on having mouse EMMA
P-values ,0.001 and EVE meta-analysis P-values ,0.001 were
KCNIP4 and PDZD2/GOLPH3/MTMR12/ZFR. While there was
some evidence of gene- or regional-level replication for both sites
among the GABRIEL and Sepracor/LOCCS/LODO/Illumina
asthma GWAS studies, only the KCNIP4 gene had evidence of
replication at individual SNPs. Additionally, only KCNIP4 SNPs
were nominally associated with AHR among asthmatics in the
SHARP AHR GWAS, indicating that this gene may be related to
both baseline AHR (i.e. AHR in the absence of asthma) and
asthma. Thus, we selected KCNIP4 as the final candidate for
replication in DAG. We found that there was additional gene-level
and SNP-level replication for KCNIP4 with asthma in DAG, and
gene-level replication for KCNIP4 with AHR in DAG.
In addition to the nominal associations we observed, other
studies have observed KCNIP4 SNP associations with asthma-
Figure 2. Baseline AHR slope phenotype distribution among 31 mouse strains. The AHR slope, displayed along the y-axis, was computed
as the slope of the resistance measures vs. log-transformed methacholine concentrations for each mouse strain. Names for each mouse strain are
displayed along the x-axis.
doi:10.1371/journal.pone.0056179.g002
Figure 3. Manhattan plot of mouse AHR slope EMMA results.
The x-axis denotes position along each chromosome. The y-axis
denotes –Log10(P) corresponding to EMMA P-values. None of the P-
values are significant after corrections for multiple comparisons, but all
those with nominal P-values ,0.001 were selected for further study.
doi:10.1371/journal.pone.0056179.g003
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induced asthma in Koreans (84 cases and 263 controls) found that
KCNIP4 SNP rs4697192 had a P-value of 6.11e-05 for association
under a recessive model [33]. Second, a family-based GWAS of
change in lung function in response to glucocorticoid therapy
among 118 asthmatics found that KCNIP4 SNP rs4282162 had a
P-value of 0.028 under a recessive model of inheritance, but
attempts to replicate this result in three independent populations
were unsuccessful [30]. Neither of these SNPs was among those
considered in Table 1. In a follow-up study of the first EVE meta-
analysis GWAS, all SNPs with meta-analysis P-values ,0.001 in
the combined sample or ,1e-04 in the race/ethnic-specific
analyses were selected for replication [28]. Five KCNIP4 SNPs,
including rs6833065 that is in Table 1, were among the SNPs
genotyped in nine different replication populations of diverse
origin (4 European American, 4 African American, 5 Latino
American), comprised of 7202 cases, 6426 controls, and 507 case-
parent trios. None of the KCNIP4 SNPs replicated the primary
EVE findings. Taken together, the KCNIP4 association results
from the current study and three previous ones suggest that if the
nominally significant associations found represent a true relation-
ship between this gene and asthma, then there is not a clear single
functional variant underlying this relationship. Rather, there are
weak effects observed at multiple sites that implicate the gene. It is
possible that more thorough genotyping of KCNIP4 in the
populations where single or few SNPs did not replicate primary
findings would uncover regions of association that further support
gene- or SNP-level replication. Future studies may also be able to
investigate whether KCNIP4 variants are associated with AHR
among non-asthmatics, as the mouse data found that KCNIP4
variants were associated with baseline AHR.
Based on the mouse and human association results, the Kv
channel interacting protein 4 (KCNIP4) emerged as the gene most
likely to be related to asthma and AHR. Current information for
this gene was gathered with the AceView tool [34]. KCNIP4 is
found on human chromosome 4, at 4p15.32, covering 1220.19 kb,
from 21950417 to 20730227 (NCBI 37, August 2010). The protein
encoded by KCNIP4 was first identified in a study searching for
proteins that interacted with presenilins, which are linked to early-
onset Alzheimer’s disease [35]. KCNIP4 was found to interact with
Figure 4. Top regions of association in mouse and human. Mouse plots near (A) Kcnip4 and (B) Pdzd2/Golph3/Mtmr12/Zfr contain –Log10 of
EMMA p-values vs. position along the corresponding mouse chromosome. Corresponding human homologous plots near (C) KCNIP4 and (D) PDZD2/
GOLPH3/MTMR12/ZFR. The x-axis denotes position along corresponding human chromosome, while the y-axis denotes –Log10(P) corresponding to
EVE p-values for the combined sample GWAS (C) or European American GWAS (D). LD between the SNPs with the lowest P-value to other SNPs in the
human plots are denoted in colors and were computed according to HapMap Phase 2 CEU data using LocusZoom [55].
doi:10.1371/journal.pone.0056179.g004
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PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e56179Figure 5. Mouse genotypes for SNPs with P-value ,0.001 in the top two association regions. A) Kcnip4 and B) Pdzd2/Golph3/Mtmr12/Zfr.
Each column corresponds to a mouse strain, ordered as displayed in Figure 2, such that AHR slope increases from left to right.
doi:10.1371/journal.pone.0056179.g005
Figure 6. Top regions of association in two independent human asthma GWAS. KCNIP4 association in A) Sepracor/LOCCS/LODO/Illumina
and C) GABRIEL. PDZD2/GOLPH3/MTMR12/ZFR association in B) Sepracor/LOCCS/LODO/Illumina and D) GABRIEL. The x-axis denotes position along
corresponding human chromosome, while the y-axis denotes –Log10(P). LD between the SNPs with the lowest P-value to other SNPs in the plots are
denoted in colors and were computed according to HapMap Phase 2 CEU data using LocusZoom [55].
doi:10.1371/journal.pone.0056179.g006
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presenilin PSEN2, and to be mostly expressed in brain. Based on
its structure, KCNIP4 belongs to the recoverin branch of calcium
binding proteins, characterized by having 4 EF-hand motifs, the
first of which does not bind calcium. In addition to being expressed
in brain, KCNIP4 is expressed in other tissues, including human
skeletal muscle. Previous studies of peptides that bind to the EF-
hands of calmodulin and other proteins that modulate intracellular
calcium levels have found that these calcium sensors may be
therapeutic targets for asthma [36]. For example, intratracheal
pretreatment of guinea pigs with a calcium-like peptide (i.e.
CALP1) that binds the EF-hands of calmodulin prior to ovalbumin
challenge, prevented the development of AHR and attenuated the
increased radical production by alveolar inflammatory cells of
ovalbumin-challenged guinea pigs [37]. Thus, one possible
mechanism by which KCNIP4 may influence asthma and AHR
is via modulation of intracellular calcium.
Mouse is a species that is commonly used in the study of asthma
genetics. Most genome-scale association studies of asthma in
mouse have been linkage studies that identified QTL for AHR
[8,9,12,13]. More recently, in silico QTL approaches have been
employed. In a study that characterized baseline AHR in female
mice from 36 strains and then used haplotype association mapping
(HAM) to identify chromosomal regions associated with AHR,
eight peaks on six chromosomes (i.e., 3, 5, 8, 12, 13, 14) with
nominal association p-values were suggested as interesting for
additional study [23]. The peak on chromosome 13 at 34.7 Mb
was found to coincide with previous mouse AHR QTL results and
was explored further to identify 29 candidate genes. Our mouse
results do not support seven of the eight peaks found in the
previous paper, but they do support the previous association on
chromosome 13: our EMMA results had a peak of 25 SNPs with
P-value 5.2e-04 in the range chr13:36611438–36707895. Human
associations for this region most strongly support the phenylalanyl-
tRNA synthetase 2, mitochondrial (FARS2) gene as involved in
asthma, with an EVE Latino American p-value of 6.4e-04 at
rs9502304. However, the associations at this SNP were not
significant among European Americans or African Americans,
leading to a combined EVE meta-analysis p-value of 0.07 and
exclusion as a top gene candidate in the current study. For the
current study, some of the phenotype data reported by Leme et al
[23] was utilized, but we extended this data by including AHR
measures from male mice. Overall, we included data for 31 strains
that had available AHR slope measures in mice of both genders
and available genotype data. In addition to utilizing more
phenotype data, we used a newer association method (i.e. EMMA)
and more complete strain genotypic data than did the previous
study. The primary advantage of EMMA vs. HAM is that EMMA
takes the known genetic similarity between strains into account to
control for population structure effects. The genome-wide
genotype data for mouse strains used in the current study were
for 281,300 SNPs, rather than 70,000 used in the previous report.
Despite these improvements, our mouse association data still
suffers from limitations. First, we are limited to a relatively small
number of strains over which the range of AHR does not vary
greatly. While the variability of AHR within strains seems to be
significantly lower than that across strains, it may be the case that
additional measures within strains would result in more precise
phenotypes that have less within-strain variability and that
increasing the number of strains phenotyped would provide a
greater range of AHR variability across strains. Second, the
phenotype studied, baseline AHR, may not be the best phenotype
to characterize asthma susceptibility. For example, measures of
AHR after mice are sensitized to ovalbumin may result in greater
phenotype heterogeneity across strains and/or less heterogeneity
within strains. Such limitations likely led the current mouse study
to have insufficient statistical power to detect associations passing
multiple comparisons correction. In addition to increasing the
number of strains characterized and including additional pheno-
types, future mouse genetic studies of asthma may be greatly
improved with resources from the Collaborative Cross [38].
Translating mouse association results to the human genome is
challenging at a genome-wide scale because of incomplete
knowledge of the human/mouse genome map. We chose a
gene-based analysis because the orthologous regions available in
HomoloGene are the most accurately mapped ones, and also
because such genes are most likely to be functionally relevant to
phenotypes that are expressed in both mouse and human. It is
Table 1. Top KCNIP4 SNP Associations.
SNP CHR BP A1 A2
EVE
P-value
GABRIEL
P-value
SLLI
P-value
DAG
P-value
Combined
Asthma P-value
SHARP AHR
P-value
DAG AHR
P-value
rs4697177 4 20369187 G T 3.0E202 1.0E203 1.9E–01 2.3E–02 1.1E–04 6.7E–01 2.0E–01
rs4696975 4 20927269 A T 1.5E–01 – 2.0E–01 3.1E–03 4.9E–03 3.3E–01 3.3E–01
rs6833065 4 21127809 C T 2.9E–04 – 2.2E–01 2.2E–01 1.1E–03 9.1E–01 5.2E–01
rs2279674 4 21129348 G T 5.4E–04 4.1E–01 2.3E–01 2.2E–01 3.6E–03 9.0E–01 5.2E–01
rs1870626 4 21141706 C G 9.3E–04 – 2.2E–01 2.0E–01 2.5E–03 8.9E–01 5.1E–01
rs11947661 4 21163270 A C 1.3E–01 – 4.6E–01 5.8E–01 3.4E–01 2.3E–03 1.4E–01
rs402802 4 21181943 A G 4.1E–01 1.2E–01 7.8E–01 4.4E–01 4.1E–01 2.0E–01 2.1E–03
rs10034603 4 21339051 G T 7.3E–04 – 4.3E–02 – 3.6E–04 7.0E–01 –
rs7378252 4 21343887 A C 7.4E–04 – 3.9E–02 5.3E–01 1.1E–03 7.3E–01 6.9E–01
rs6448072 4 21352329 C T 6.8E–03 4.6E–02 3.6E–02 5.3E–01 2.2E–03 8.3E–01 7.1E–01
rs6856781 4 21368864 C T 1.1E–02 4.1E–02 3.8E–02 – 1.2E–03 7.2E–01 –
rs7664617 4 21471526 C G 2.0E–02 – 1.5E–03 3.8E–01 8.9E–04 7.3E–01 4.1E–01
Table includes SNPs that have EVE P-value ,0.001, are the lowest in individual GWAS (indicated in bold), or have nominally significant (i.e. P-value,0.05) replications in
three of four asthma GWAS. P-values in asthma replication GWAS are 1-sided, based on the effect direction in EVE, to ensure that associations reported have effects in
consistent directions. Fisher combined P-values are based on the populations with available results. *SLLI=Sepracor/LOCCS/LODO/Illumina.
doi:10.1371/journal.pone.0056179.t001
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are determinants of baseline AHR in mice. Thus, future studies
with improved mouse/human genome maps may uncover
additional regions of interest.
In summary, integration of genome-wide association results for
a mouse strain survey of baseline AHR with human asthma and
AHR GWAS results suggests that KCNIP4 is a gene related to both
asthma and AHR. Functional studies are required to validate the
potential involvement of this gene in asthma and to understand
how specific SNPs may modulate asthma susceptibility and/or
AHR.
Methods
Mouse Airway Responsiveness Measures
A survey of AHR was conducted in males of 33 mouse strains,
to augment a survey of AHR that was previously conducted in
females of 36 mouse strains [23]. AHR was measured by gathering
a baseline resistance reading for 6–10 mice per strain and gender,
followed by a reading after administration of saline, and
sequentially increasing concentrations of methacholine (1, 3, 10,
30 mg/ml) administered via nebulizer through a tracheostomy
[23]. AHR was quantified as the slope of the resistance vs. log-
transformed methacholine concentration.
Mouse in silico Association Mapping
Of the 33 mouse strains with AHR phenotype data in males and
the 36 mouse strains with AHR phenotype data in females, a
subset of 31 strains overlapped and had genome-wide genotype
data available. This subset of 31 mouse strains with AHR
measures in both males and females and with available genotype
data was used to conduct association analyses. The association of
SNPs with AHR was measured using Efficient Mixed Model
Association (EMMA) software [19], which uses a linear mixed
model with a variance component using a kinship matrix that is
based on the genetic similarity between strains to control for
population structure effects. The genotype data for the mouse
strains was part of the ‘‘Subspecific Origin and Haplotype
Diversity in the Laboratory Mouse’’ project of the Jackson
Laboratory available at http://cgd.jax.org/datasets/popgen/
diversityarray/yang2011.shtml [39]. Autosomal chromosome
association results obtained with male and female mice were
utilized. Monomorphic and singleton SNPs were excluded, and
the final dataset contained association results for 281,300 SNPs.
Primary Human Asthma GWAS
The primary group of subjects consisted of participants of the
EVE consortium, which comprises nine research teams in the
USA with genome-wide association data for diverse asthma
cohorts [26]. Briefly, 4,867 European Americans (1,486 cases,
1,539 controls, and 620 trios), 4,644 Latinos (606 cases, 792
controls, and 1,082 trios), and 3,447 African Americans (1,154
cases, 1,054 controls, and 413 trios) recruited through clinics and
health systems in the U.S., Puerto Rico, Mexico, and Barbados
were used in a meta-analysis of GWAS of asthma. The previously
generated meta-analysis results for .2 million SNPs, based on
genotyped or HapMap Phase 2 imputed data, for all subjects, as
well as those limited to European American, African American,
and Latino American groups were utilized. The test statistic to
assess association of SNPs with asthma was based on a linear
combination of normally distributed test statistics weighted by the
square root of individual study sample sizes. Significance of this
test statistic was assessed using standard normal approximations
[26,28].
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1) Sepracor/LOCCS/LODO/Illumina. This cohort con-
sisted of 531 non-Hispanic white cases with mild to severe asthma
from three adult asthma populations: (1) a medication trial
conducted by Sepracor, Inc., US [40,41]; (2) the Leukotriene
Modifier or Corticosteroid Salmeterol (LOCCS) study [42]; and
(3) the Effectiveness of Low Dose Theophylline as an Add-on
Treatment in Asthma (LODO) trial [43]. Cases were matched
with 660 population controls obtained from Illumina’s IconDB
resource (http://www.illumina.com/science/icontroldb.ilmn) us-
ing the genetic matching (GEM) algorithm [44]. Genome-wide
genotyping of cases was performed on the Illumina 610 quad
platform. Genome-wide genotyping of controls was performed on
the Illumina HumanHap 550K v3 platform. Genotypes of SNPs of
interest that were not captured by the genotype data were inferred
using imputation with the Markov Chain Haplotyping software
(MaCH) [45] based on HapMap Phase 2 Release 22 data [46].
The ratio of the empirically observed dosage variance to the
expected (binomial) dosage variance for imputed SNPs utilized
was greater than 0.3, indicating good quality of imputation.
Dosage data was used to compute association statistics with
PLINK [47]. The corresponding genetic inflation factor was 1.04,
demonstrating minimal population stratification.
Table 3. Effect Sizes of Top KCNIP4 SNP Associations.
SNP
Reference
Allele EVE GABRIEL SLLI DAG SHARP AHR DAG AHR
rs4697177 G 0.95 [0.87, 1.03] 0.94 [0.90, 0.98] 0.92 (0.09) 0.87 0.98 [0.88, 1.09] 0.12
rs4696975 A 1.06 [0.93, 1.22] – 1.13 (0.15) 1.44 1.10 [0.91, 1.32] 0.17
rs6833065 C 1.13 [1.03, 1.22] – 1.07 (0.09) 1.06 1.01 [0.90, 1.13] 20.06
rs2279674 G 0.88 [0.81, 0.96] 1.00 [0.95, 1.04] 0.93 (0.09) 0.95 0.99 [0.88, 1.11] 20.06
rs1870626 C 1.12 [1.02, 1.21] – 1.08 (0.09) 1.06 1.01 [0.90, 1.13] 20.06
rs11947661 A 1.02 [0.94, 1.10] – 1.01 (0.08) 0.99 0.84 [0.76, 0.94] 0.12
rs402802 A 1.04 [0.96, 1.13] 1.02 [0.98, 1.06] 0.94 (0.08) 1.01 1.07 [0.96, 1.19] 20.27
rs10034603 G 0.92 [0.85, 1.00] – 0.86 (0.09) – 1.02 [0.92, 1.14] –
rs7378252 A 1.07 [0.99, 1.16] – 1.16 (0.09) 0.99 0.98 [0.88, 1.09] 20.04
rs6448072 C 0.93 [0.85, 1.01] 0.97 [0.93, 1.01] 0.86 (0.09) 1.01 1.01 [0.91, 1.13] 20.03
rs6856781 C 1.07 [0.98, 1.16] 1.04 [1.00, 1.08] 1.17 (0.09) – 0.98 [0.88, 1.09] –
rs7664617 C 0.94 [0.86, 1.03] – 0.78 (0.09) 0.98 1.02 [0.92, 1.13] 0.07
Odds ratios are shown for asthma (EVE combined cohort, GABRIEL, Sepracor/LOCCS/LODO/Illumina (SLLI), and DAG) and for AHR (SHARP AHR for change in LnPC20,
DAG AHR for change in Ln(Slope)). EVE, GABRIEL, and SHARP include 95% confidence intervals. SLLI includes standard errors.
doi:10.1371/journal.pone.0056179.t003
Figure 7. Top regions of association in a human AHR GWAS. (A) KCNIP4 and (B) PDZD2/GOLPH3/MTMR12/ZFR associations in SHARP. The x-
axis denotes position along corresponding human chromosome, while the y-axis denotes –Log10(P). LD between the SNPs with the lowest P-value to
other SNPs in the plots are denoted in colors and were computed according to HapMap Phase 2 CEU data using LocusZoom [55].
doi:10.1371/journal.pone.0056179.g007
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asthma consisted of 10,365 persons with physician-diagnosed
asthma and 16,110 unaffected persons, all of whom were matched
for ancestry [25]. Publicly available results for the random-effects
pooled analysis that tested for association using the entire study
population with asthma were used [Available at http://www.cng.
fr/gabriel/results.html].
3) Dutch asthma GWAS (DAG). This cohort was comprised
of 920 DAG subjects with doctor-diagnosed asthma and docu-
mented AHR and 985 controls [48,49]. Genotyping was
performed using the Hapmap 317K platform or Illumina 370
Duo Chip. Tests of association were performed via logistic
regression using PLINK.
Human AHR GWAS
1) SHARP. A GWAS of AHR, quantified as the natural log of
the dosage of methacholine causing a 20% drop in FEV1, was
performed with 994 non-Hispanic white asthmatic subjects from
the Childhood Asthma Management Program (CAMP) [50], and
subsets of clinical trials within the Childhood Asthma Research
and Education (CARE) network [51], and the Asthma Clinical
Research Network (ACRN) [52] participating in the NHLBI SNP
Health Association Resource Asthma Resource project (SHARP)
[53]. Genome-wide SNP genotyping for SHARP subjects was
performed by Affymetrix, Inc. (Santa Clara, CA) using the
Affymetrix Genome-Wide Human SNP Array 6.0. Imputation of
all SNPs available in HapMap Phase 2 Release 22 CEU data
using MaCH [45] was performed. The primary GWAS was based
on imputed SNPs with minor allele frequency (MAF) .0.05 and a
ratio of empirically observed dosage variance to the expected
(binomial) dosage variance greater than 0.3, indicating good
quality of imputation. The association of SNPs with LnPC20 was
measured with a linear regression model using dosage data as
implemented in PLINK.
2) Dutch asthma GWAS (DAG). This cohort was comprised
of 650 DAG subjects with doctor-diagnosed asthma and docu-
mented AHR [48,49]. All subjects had smoking history and steroid
use data available at the time of the AHR test. Participants with a
history of AHR but in remission during the test were excluded.
Remission was defined as not on steroids and without 20% or
greater fall in FEV1 during the AHR test. The AHR test was
conducted using histamine or methacholine as a stimulus. AHR
was quantified as the difference between FEV1 at baseline and at
the dose step at which a 20% or greater FEV1 drop was achieved,
divided by the dose of stimulant used (slope). Because two
protocols were used, one with a 30-second tidal breathing method
and a second with a 2-minute tidal breathing phase, the AHR
slopes measured with the 30-second tidal breathing method were
divided by 4, in order to compensate for the 4 times greater
duration of administration of stimulus. Slope values were log-
transformed so that they would follow a normal distribution.
Genotyping was performed using the Hapmap 317K platform or
Illumina 370 Duo Chip. Tests of AHR association were performed
via linear regression, with smoking and inhaled/oral steroid use as
covariates using PLINK.
Each study was approved by its respective Institutional Review
Board, which ensured that all procedures followed were in
accordance with the ethical standards of the responsible committee
on human experimentation. Informed consent was obtained for all
study participants.
Integration of Mouse and Human GWAS Results
Mouse gene coordinates were mapped to the human genome
using the mouse comparative homology map data corresponding
to Mouse Build 37.2, Human Build 37.2 and HomoloGene file
from April 15, 2011 available at ftp://ftp.ncbi.nih.gov/pub/
homology_maps/ [54]. After selection of orthologous genes, the
list of genes was restricted based on having an EVE meta-analysis
P-value ,0.001 in one of the race/ethnic-specific analyses or in
the combined GWAS. Plots of human association results near
specific genes were created using LocusZoom with the hg18/
HapMap Phase II CEU GenomeBuild/LD Population [55].
Combined P-values with replication populations were computed
using Fisher’s combined probability method [56] where hypothesis
tests in replication populations had one-sided alternatives, based
on the direction of the association in EVE, so that SNPs with
association tests in opposite directions would not produce
inappropriately small P-values. Analyses were carried out using
the R computing environment [57].
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